The trial will determine the safety, tolerability and preliminary efficacy of nivolumab, Bristol-Myers' investigational PD-1 immune checkpoint inhibitor, and varlilumab, Celldex's CD27 targeting investigational antibody in a Phase 1/2 study. The study will explore multiple tumor types, which potentially include non-small cell lung cancer, metastatic melanoma, ovarian, colorectal and squamous cell head and neck cancers.
Bristol-Myers Squibb will make a one-time payment of $5 million to Celldex under the terms of the agreement, and the two companies will share development costs. Celldex will conduct the Phase 1/2 study, which should start in the fourth quarter of 2014.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts